Leronlimab (anti-CCR5)

Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the
CCR5 receptor found on T lymphocytes of the human immune system. It is being
investigated as a potential therapy in the treatment of COVID-19.
The United States Food and Drug Administration has designated PRO 140 for fast-track
approval . In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was
begun in 2015.